Close Menu

NEW YORK (GenomeWeb) – Cancer informatics and precision medicine firm Tempus said today that it has raised $110 million in a Series E financing round.

Participants in the round included Baillie Gifford, funds and accounts managed by T. Rowe Price, Revolution Growth, New Enterprise Associates, and other existing investors.

Tempus, based in Chicago, said that it will use the additional funds to grow operations and expand into new therapeutic areas and geographies.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The Guardian reports that the Mammalian Genetics Unit at the Harwell Institute is to close.

Scientific research itself contributes to plastic waste and isn't very sustainable, FiveThirtyEight reports.

Restaurants in the US may soon serve AquaBounty's genetically modified salmon, according to the Associated Press.

In Science this week: three studies from the Ruminant Genome Project, and more.